Live Breaking News & Updates on Christoph antz

Stay informed with the latest breaking news from Christoph antz on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Christoph antz and stay connected to the pulse of your community

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline

Xlife Sciences AG / Key word: Mergers & Acquisitions/Takeover

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
29-Dec-2023 / 17:45 CET/CEST

Release of an ad hoc...

Christoph-antz , Oliverr-baumann , Synimmune-gmb , Xlife-sciences , Synimmune-gmbh , Acute-myeloid-leukemia , Acute-myeloid , Shareholders-meeting , Year-report , Markets ,

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline - adhoc - Börsennachrichten

Xlife Sciences AG Key word Mergers & AcquisitionsTakeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29Dec2023 1745 CETCEST Release of an ad hoc announcement pursuant to

Synimmune-gmb , Christoph-antz , Oliverr-baumann , Xlife-sciences , Synimmune-gmbh , Acute-myeloid-leukemia , Acute-myeloid , Shareholders-meeting , Year-report , Xlife , Ciences , Ergers

Torsten Buergermeister Joins VERAXA Biotech GmbH as Chief Financial Officer

The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.HEIDELBERG, Germany, March 22, 2022 / B3C newswire / -- Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany. Buergermeister...

Germany , Heidelberg , Baden-wüberg , Christoph-antz , Araxa-biosciences-gmb , Torsten-buergermeister , Molecular-health , European-molecular-biology-laboratory , Chief-financial-officer , Precision-medicine , Senior-vice-president , Velabs-therapeutics-gmbh

VERAXA Biotech GmbH Appoints Dr. Lars Hufnagel to Chief Technical Officer

Lars Hufnagel will be responsible for advancing VERAXA’s antibody screening and ADC technologies by further developing its droplet-based microfluidic screening technology.HEIDELBERG, Germany, March 14, 2022 / B3C newswire / -- Dr. Lars Hufnagel has been appointed Chief Technical Officer (CTO) of VERAXA Biotech, base...

Germany , Heidelberg , Baden-wüberg , Lars-hufnagel , Christoph-antz , Araxa-biosciences-gmb , Bruker-corporation , European-molecular-biology-laboratory , Group-leader-of-the-cell-biology , Chief-technical-officer , General-manager , Vice-president

VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development

Search jobs
VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development
HEIDELBERG, Germany and ZUG, Switzerland, June 14, 2021 / B3C newswire / --VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), a leading company in innovative ADC engineering and functional antibody screening, announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of oncological conditions. The collaboration will leverage both the advantages of VERAXA's advanced and proprietary position-true click-chemistry-based drug conjugation technology in combination with Quadira’s superior 3D cellular assay and assessment systems. The agreement provides that VERAXA will be entitled to upfront payments and royalties from the worldwide sale of products resulting from the collaboration. Further details of the agreement were not disclosed.

Germany , Heidelberg , Baden-wüberg , Switzerland , Swiss , Araxa-biosciences-gmb , Christoph-antz , Quadira-biosciences , Arne-faiss , Xlife-sciences , European-molecular-biology-laboratory , Velabs-therapeutics-gmbh